ReviewFrontiers in cellular and infection microbiology2019
Review in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 95 citations in OpenAlex.
- γδ T Cells at the Crossroads of Tuberculosis and COPD: From Early Immunity to Tissue Remodeling.International journal of molecular sciences · 2026Review
- Mycobacterium tuberculosis infects human peripheral hematopoietic multipotent progenitors and promotes their myeloid differentiation in vitro.Cell death & disease · 2026Article
- Article
- Human lung organoids model for assessing host response toFrontiers in cellular and infection microbiology · 2026Article
- Structural and Functional Characterization of Protein Adhesins and Pili in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Article
- Innate immune recognition ofCell surface (Amsterdam, Netherlands) · 2025Review
- A DNA Methylation Signature From Buccal Swabs to Identify Tuberculosis Infection.The Journal of infectious diseases · 2025Article
- RapTB: a lung-derived hemoglobin fragment with activity againstFrontiers in microbiology · 2025Article
- Progress in the role of nanoparticles in the diagnosis and treatment of bone and joint tuberculosis.Frontiers in medicine · 2025Review
- Intestinal microbiome dysbiosis increaseseLife · 2024Article
- Metabolically active neutrophils represent a permissive niche for Mycobacterium tuberculosis.Mucosal immunology · 2024Article
- Article
- Nontuberculous Mycobacteria, Mucociliary Clearance, and Bronchiectasis.Microorganisms · 2024Review
- Characterizing the immune response toFrontiers in immunology · 2024Review
- Article
- Tackling Drug-Resistant Tuberculosis: New Challenges from the Old PathogenMicroorganisms · 2023Review
- In Silico Development of Novel Benzofuran-1,3,4-Oxadiazoles as Lead Inhibitors ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Nanosized Drug Delivery Systems to Fight Tuberculosis.Pharmaceutics · 2023Review
- Early innate cell interactions withFrontiers in immunology · 2023Review
- Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection againstVirulence · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Globally, tuberculosis (TB) has reemerged as a major cause of morbidity and mortality, despite the use of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.